HC Wainwright & Co. Maintains Buy on ProPhase Labs, Raises Price Target to $16
HC Wainwright & Co. analyst Yi Chen maintains ProPhase Labs (NASDAQ:PRPH) with a Buy and raises the price target from $15 to $16.
ProPhase Labs Earnings Preview
ProPhase Labs (NASDAQ:PRPH) is set to give its latest quarterly earnings report on Wednesday, 2022-03-30. Here's what investors need to know before the announcement.
Analysts estimate that ProPhase Labs will report an earnings per share (EPS) of $0.44.
HC Wainwright & Co. Maintains Buy on ProPhase Labs, Raises Price Target to $15
HC Wainwright & Co. analyst Yi Chen maintains ProPhase Labs (NASDAQ:PRPH) with a Buy and raises the price target from $12 to $15.
HC Wainwright & Co. Initiates Coverage On ProPhase Labs with Buy Rating, Announces Price Target of $12
HC Wainwright & Co. analyst Yi Chen initiates coverage on ProPhase Labs (NASDAQ:PRPH) with a Buy rating and announces Price Target of $12.
Earnings Scheduled For November 12, 2021
Companies Reporting Before The Bell
• Zevia (NYSE:ZVIA) is estimated to report quarterly loss at $0.43 per share on revenue of $34.40 million.
Dawson James Downgrades ProPhase Labs to Neutral
Dawson James analyst Jason Kolbert downgrades ProPhase Labs (NASDAQ:PRPH) from Buy to Neutral.
Benzinga Pro’s Top 5 Stocks To Watch For Monday, Oct. 11, 2021: SOFI, PTGX, GTLB, PRPH, AVDL
Today's 5 Stock Ideas:
SoFi Technologies (SOFI) - Shares were up 4% following initiation of coverage by a Morgan Stanley analyst. The analyst set an Overweight rating (the equivalent of a buy) and a set a $25
Recap: ProPhase Labs Q2 Earnings
Shares of ProPhase Labs (NASDAQ:PRPH) rose 3.1% in pre-market trading after the company reported Q2 results.
Quarterly Results
Earnings per share were down 1000.00% over the past year to ($0.09), which missed the estimate of $0.33.